Clinical Trial Highlights

A strong global footprint NORTH AMERICA 32% OF TOTAL SALES 40+ countries with Ipsen presence Γ REST OF WORLD 28% OF TOTAL SALES L EUROPE 40% OF TOTAL SALES 110+ countries where Ipsen medicines are marketed IPSEN Innovation for patient care Based on H1 2023 total sales. In this presentation, Europe is defined as the E.U., the U.K., Iceland, Liechtenstein, Norway and Switzerland. 18 L

View entire presentation